Characterization and Outcome of “Hard to Mobilize” Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

References

• Jones H. M., Jones S. A., Watts M. J., Khwaja A., Mills W., Fielding A., Glodstone A. H., Linch D. C. Development of simplified apheresis approach for PBSC transplanvation in previously treated patients with lymphoma. Journal of Clinical Oncology 1994; 12: 1693–1702
   PubMed Web of Science ®Google Scholar
• Beyer J., Schwella N., Zingsem J., Strohscheer I., Schwaner I., Oettle H., Serke S., Huhn D., Stieger W. Hemntopoietic rescue after high-dose chemotherapy using autologous peripheral blood progenitor cells or bone marrow: a randomized comparison. Journal of Clinical Oncology 1995; 13: 1328–1335
   PubMed Web of Science ®Google Scholar
• Schmitz N., Linch D. C., Dreger P., Goldstone A. H., Boogaerts M. A., Ferrant A., Demuynck H. M., Link H., Zander A., Barge A. Randomized trial of filgrastim mobilized peripheral bld progenitor cell transplant versus autologous hone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357
   PubMed Web of Science ®Google Scholar
• Smith T. J., Hillner B. E., Schmitz N., Linch D. C., Dreger P., Goldstone A. H., Boogaerts M. A., Ferrant A., Link H., Zander A., Yanovich S., Kitchin R., Erder M. H. Economic analysis of a randomized clinical trial to compare lilgrastim-mobilized peripheral blood transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. Journal of Clinical Oncology 1997; 15: 5–10
   PubMed Web of Science ®Google Scholar
• Damiani D., Fanin R., Silvestri F., Grimaz S., Infanti L, Geromin A., Cerno M., Michieli M., Rinaldi C., Savignano C., Trani G., Fiacchini M., Baccarani M. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation with lymphoma patients. Blood 1997; 90: 36–42
   PubMed Web of Science ®Google Scholar
• Janssen W E, Smilee R C, Elfenbein G J. A prospective randomized trial comparing blood- and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy. Journal of Hemarotherapy 1995; 4: 139–140
   PubMedGoogle Scholar
• Bender J G, Williams S F, Myers S, Nottleman D., Lee W. J., Unverzagt K. L., Walker D., To L. B., Van Epps D. E. Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologoous stem cell transplantation. Bone Marrow Transplantution 1992; 10: 281–285
   PubMed Web of Science ®Google Scholar
• Ho A. D., Gluck S., Germond C., Sinoff C., Dietz G., Maru-Yama M., Curringham R. E.T. Optimal timing for collection of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 1993; 7: 1738–1746
   PubMed Web of Science ®Google Scholar
• Hohaus S., Goldschmidt H., Ehrhardt R., Haas R. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Experimental Hematology 1993; 21: 508–514
   PubMed Web of Science ®Google Scholar
• Bensinger W. I., Longin K., Appelbaum F., Rowley S., Weaver C., Lileby L. C., Goley T., Lynch M., Higano T., Klarnet J., Chauncey T., Storb R., Buckner C. D. Peripheral blood stem cells (PBSCs) collected after recombinant graluncyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. British Journal Haematology 1994; 87: 815–831
   Web of Science ®Google Scholar
• Haas R., Mohle R., Murea S., Goldschmidt H., Pforsich M., Witt B., Hunstein W. Characterization of peripheral blood progenitor cells mobilized by cytotoxic chemotherapy and recombinant human granulocyte colony-stimulating factor. Journal of Hematotherapy 1994; 3: 323–330
   PubMedGoogle Scholar
• Weaver C. H., Hazelton B., Birch R., Palmer P., Allen C., Schwartzberg L., West W. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969
   PubMed Web of Science ®Google Scholar
• Watts M. J., Sullivan A. M., Jamieson E., Pearce R., Fielding A., Devereux S., Goldstone A. H., Linch D. C. Cyclophosphamide and granulocyte colony- stimulating factor: an analysis of progenitor cell quantity and quality and factors predicting for these parameters in 101 pre-treated patients with malignant lymphoma. Journal of Clinical Oncology 1997; 15: 535–546
   PubMed Web of Science ®Google Scholar
• Weaver C. H., Potz J., Redmond J., Tauer K., Schwartzberg L. S., Kaywin P., Drapkin R., Grant B., Unger P., Allen C., Longin K., Zhen B., Hazelton B., Buckner C. D. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content. Bone Morrow Transplantation 1997; 19: 1103–1110
   PubMed Web of Science ®Google Scholar
• Sugrue M. W., Williams K. D., Hutcheson C. E., Fisk D. D., Roberts C. G., Wingard J. R., Moreb J. S. Characterization of a patient population in whom an optimal autologous peripheral blood stem cell dose cannot be achieved (abstract). Journal of Hematotherapy 1998; 7: 267
   Google Scholar
• Waples J. M., Moreb J. S., Sugrue M., Belanger G., Kubilis P., Lynch I. W., Gian V., Weeks F., Wingard J. Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Morrow Transplantation 1999; 23: 867–873
   PubMed Web of Science ®Google Scholar
• Ketterer N., Salles G., Moullet I., Dumontet C., Eljaafari C. A., Tremisi P., Thieblemont C., Durand B., Neidhardt B. E.M., Samaha H., Rigal D., Coiftier B. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. British Journal of Haematology 1998; 103: 235–242
   PubMed Web of Science ®Google Scholar
• Visani G., Lemoli M., Tosi P., Martinelli G., Testoni N., Ricci P., Piccaluga P. P., Pastano R., Leopardi G., Dizdari A., Motta M. R., Rizzi S., Tura S. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukemia patients. Brush Journal of Haematology 1999; 105: 775–779
   PubMed Web of Science ®Google Scholar
• Hacis R., Mohlc R., Fruhaul S., Goldschiuidt H., Witt B., Fientjc M., Wannanmahcr M., Hunstein W. Patient characteristics associated with successful mobilizing and auto grafting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794
   PubMed Web of Science ®Google Scholar
• Passes-Coelho J. L., Braine H. G., Davis J. M., Huelshamp A-M., Sehapers K. G., Ohly K., Clarke B., Wright S. K., Dnvidson S. E., Noga N. E., Kennedy M. J. Predictive liictors lw peripheral-blood progenitor cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. Journal of Clinical Oncology 1995; 13: 705–714
   PubMed Web of Science ®Google Scholar
• Bensinger W., Appelbaum F., Rowley S., Storb R., Sanders J., Lilleby K., Gaoley T., Demirer T., Schiffman K., Weaver C., Clifi R., Chauncey T., Klarnet J., Montgomery P., Petersdorf S., Weiden P., Witherspoon R., Buekner C. D. Factors that influence collection and engraftment of aulologous peripheral blood stem cells. Journal of Clinical Oncology 1995; 13: 2547–2555
   PubMed Web of Science ®Google Scholar
• Dreger P., Kloss Peterson M. H., Haferlach T., Loffler H., Loffler M., Schmitz N. Autologous progenitor cell transplantation Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1997; 86: 3970–3978
   Web of Science ®Google Scholar
• Weaver C. H., Tauer K., Zhen B., Schwartzberg L. S., Hazelton B., Weaver Z., Lewkow L., Allen C., Longin K., Buckner C. D. Second attempts at mobilization of peripheral stem cells in patients with initial low CD34+ cell yields. Journal of Hematotherapy 1998; 7: 241–249
   PubMedGoogle Scholar
• Gazitt Y., Freytet C. D., Callender N., Tsai T-W., Alsina M., Anderson J., Holle L., Cruz J., Devore P., McGrath M., West G., Alvarez R., Montgomery W. Successlul PHSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. Journal of Hematotherapy 1999; 8: 173–183
   PubMedGoogle Scholar
• Still P. J. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplantation 1999; 23(Suppl 2)S29–33
   PubMed Web of Science ®Google Scholar
• Scott M. A., Ager S., Jestice H. K., Mahendra P., Marcus R. E. Failure to mobilize and harvest PBPC does not necessarily preclude the use or high-dose therapy and autologous stem cell rescue. Bone Marrow Transplantation 1995; 15: 487–488, Letter
   PubMed Web of Science ®Google Scholar
• Watts M. J., Sullivan A. M., Leverett D., Peniket A. J., Perry A. R., Williams C. D., Devereux S., Goldstone A. H., Linch D. C. Back-up hone marrow is frequently ineffective in patients with poor peripheral-blood stem cell mobilization. Journal of Clinical Oncology 1998; 16: 1554–1560
   PubMed Web of Science ®Google Scholar
• Haas R., Hohaus S., Egerer G., Ehrhardt R., Witt B., Hunstein W. Recombinant human granulocyte macrophage-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cell for auto grafting in patients not eligible for bone marrow harvest. Bone Marrow Transplantation 1992; 9: 459–465
   PubMed Web of Science ®Google Scholar
• Boiron J. M., Marit G., Faberes C., Cony-Makhoul P., Faires C., Ferrer A. M., Cristol G., Sarrat A., Girault D., Reiffers J. Collection of peripheral blood stem cells in multiple myeloma following single high-close cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplantation 1993; 12: 49–55
   PubMed Web of Science ®Google Scholar
• Venturini M., Del Mastro I., Melioli G., Balleari E., Garrone O., Pasquctti W., Bison C., Ghio R., Bruzzi P., Rosso R. Release of peripheral blood progenitor cells during standard dose cyclophosphamide. Epidoxorubicn 5-tluorou-racil regimen plus granulocyte colony stimulating factor for breast cancer therapy. Cancer 1991; 74: 2300–2306
   Web of Science ®Google Scholar
• Weaver C. H., Schwartzberg L. S., Birch R., Greco F. A., Rhinehart S., Hainesworth J., Beeker T., Price H., Geier L., Foster J., West J., Hazelton B., Buckner C. D. Collection ot peripheral blood progenitor cells after the administration of cyclophosphamide. etoposide and granulocyte-colony-stimulating factor An analysis of 497 patients. Transfusion 1997; 37: 896–903
   PubMed Web of Science ®Google Scholar
• Damirer T, Buckner C. D., Storer B., Lilleby K., Rowley S., Clift R., Appelbaum F. R., Storb K., Bensinger W. I. Effect of different chemotherapy regimens on peripheral blood cancer receiving cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. Journal of Clinical Oncology 1997; 15: 681–690
   Web of Science ®Google Scholar
• Kolbe Peschel K. C., Rupilius B., Dcspres D., Burger K., Sklcnar I., Farber I., Huber C., Derigs H. G. Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pre-treated patients. Bone, Marrow Transplantation 1997; 20: 1027–1032
   PubMed Web of Science ®Google Scholar
• Shpall E. J., Wheeler C. A., Turner S. A., Yanovich S., Borwn R. A., Pecora A. L., Shea T. C., Mangan K. F., Williams S. F., Le Mastre C. F., Long G. D., Jones R., Davis M. W., Mur-phy-Filkins R., Parker W. R., Glaspy J. A. A randomized Phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999; 93: 2191–2501
   PubMed Web of Science ®Google Scholar
• Facan T., Harousseau J. L., Maloisel Attal E. M., Odriozola J., Alegre A., Schroyens W., Hulin C., Sehots K., Martin P., Guibot Grancna F. A., Dc-Wacle M., Peigneux A., Meresse V., Clark P., Reiffers F. (Stem cell factor in combination with filtrate after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 1999; 94: 1218–1225
   PubMed Web of Science ®Google Scholar
• Fleming W. H., Lankford-Turner P., Turner C. W., Wong J., Strobert E., McKean J. P. Administration of' daniplestim and granulocyte colony-simulating factor for the mobilization of hematopoietic progenitor cells in nonhuman primates. Biology of Blood and Marrow Transplantation 1999; 5: 8–14
   PubMedGoogle Scholar
• Di Persio J. F., Vredenburg J., Copelan E. A., Prosper F., Sola C., Lill M., Bolwell B. J., Santos V. R., Collins D. M., Baum C. M. Prospective randomzied study of peripheral blood stem cell (PBSC) mobilization with daniplestim plus G-CSP versus placebo plus G-CSF in breast cancer patients (abstract). Blood 1998; 92(suppl)269a
   Google Scholar